Exact Sciences (EXAS) Misses Q3 EPS by 1c, Lowers Guidance
Tweet
Share
E-mail
Get Alerts EXAS Hot Sheet
Financial Fact:
Research and development: 7.63M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $709 million versus the consensus estimate of $716.8 million.
GUIDANCE:
Exact Sciences sees FY2024 revenue of $2.73-2.75 billion, versus the consensus of $2.83 billion.
The Company has updated its full-year 2024 revenue and adjusted EBITDA guidance:
| Prior guidance |
| November 5 update |
Total revenue | $2.810 - $2.850 billion |
| $2.730 - $2.750 billion |
Screening | $2.155 - $2.175 billion |
| $2.080 - $2.095 billion |
Precision Oncology | $655 - $675 million |
| $650 - $655 million |
Adjusted EBITDA | $335 - $355 million |
| $310 - $320 million |
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance
- Bernstein SocGen Group Resumes Thermo Fisher Scientific (TMO) at Market Perform
- Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
